48 results match your criteria: "French Reference Center on Paraneoplastic Neurological Syndrome[Affiliation]"
Neuro Oncol
May 2018
Department of clinical immunology, Pavillon O, Edouard Herriot University Hospital, Hospices Civils de Lyon, Lyon, France.
Neurol Neuroimmunol Neuroinflamm
January 2018
French Reference Center on Paraneoplastic Neurological Syndrome (A.B., B.J., V.R., J.H.), Hospices Civils de Lyon, Hôpital Neurologique, Bron, France; Institut NeuroMyoGene INSERM U1217/CNRS UMR 5310 (A.B., B.J., V.R., J.H.), Université de Lyon-Université Claude Bernard Lyon 1, France; Stanford Blood Center (G.M.-M., M.F.-V., E.M.), Histocompatibility, Immunogenetics & Disease Profiling Laboratory, Palo Alto, CA; Immunology, Hospices Civils de Lyon (N.F.), Hôpital Lyon-Sud, France; and Stanford University Center for Sleep Sciences and Medicine (E.M), Palo Alto, CA.
Objective: Neurologic autoimmune syndromes associated with anti-glutamate acid decarboxylase 65 antibodies (GAD65-Abs) are rare and mostly sporadic.
Methods: We describe a niece and her aunt with GAD65-Abs neurologic syndromes. High-resolution HLA typing of Class I and Class II alleles was performed using next-generation sequencing.
J Neuroimmunol
February 2018
Center for Sleep Sciences and Medicine, Stanford University, 3165 Porter Drive, Palo Alto, CA 94304, USA. Electronic address:
Anti-Yo paraneoplastic cerebellar degeneration (PCD) is a devastating autoimmune complication of gynecological cancers. We hypothesized that as for other autoimmune diseases, specific HLA haplotypes are associated. We conducted high resolution HLA typing of Class I/Class II in 40 cases versus ethnically matched controls.
View Article and Find Full Text PDFActa Neuropathol
April 2018
Institut NeuroMyogène, Equipe Synaptopathies et Autoanticorps (SynatAc), INSERM U1217/UMR CRS 5310, Lyon, France.
Paraneoplastic cerebellar degenerations with anti-Yo antibodies (Yo-PCD) are rare syndromes caused by an auto-immune response against neuronal antigens (Ags) expressed by tumor cells. However, the mechanisms responsible for such immune tolerance breakdown are unknown. We characterized 26 ovarian carcinomas associated with Yo-PCD for their tumor immune contexture and genetic status of the 2 onconeural Yo-Ags, CDR2 and CDR2L.
View Article and Find Full Text PDFNeurology
March 2017
From the Laboratorio de Neurología (E.T.-V., T.S., J.J.V., L.B.), Instituto de Investigación Sanitaria La Fe, Hospital Universitario y Politécnico La Fe, CIBERER, Valencia; Servicio de Anatomía Patológica (N.M.), Servicio de Neurofisiología Clínica (M.J.C.), and Servicio de Neurología (T.S., J.J.V., L.B.), Hospital Universitario y Politécnico La Fe, Valencia; Laboratorio de Neurobiología Comparada (A.C.-S., V.H.-P., J.M.G.-V.), Instituto Cavanilles, Universidad de Valencia, CIBERNED; Servicio de Neurología (G.M.), Hospital Central de Asturias, Oviedo, Spain; French Reference Center on Paraneoplastic Neurological Syndrome (B.J., J.H.), Hospices Civils de Lyon, Hôpital Neurologique, Bron, and Institut NeuroMyoGene INSERM U1217/CNRS UMR 5310, Université de Lyon-Université Claude Bernard Lyon 1, France; Laboratori de Neurologia (J.D., F.G.), Institut d´Investigacions Biomèdiques August Pi I Sunyer, CIBERER, Barcelona, Spain; and Department of Neurology (J.D.), University of Pennsylvania, Philadelphia, and Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain.
Objective: To identify cell-surface antibodies in patients with neuromyotonia and to describe the main clinical implications.
Methods: Sera of 3 patients with thymoma-associated neuromyotonia and myasthenia gravis were used to immunoprecipitate and characterize neuronal cell-surface antigens using reported techniques. The clinical significance of antibodies against precipitated proteins was assessed with sera of 98 patients (neuromyotonia 46, myasthenia gravis 52, thymoma 42; 33 of them with overlapping syndromes) and 219 controls (other neurologic diseases, cancer, and healthy volunteers).
Neurology
February 2017
From the French Reference Center on Paraneoplastic Neurological Syndrome (L.-D.D., E.C., V.D., B.J., F.D., V.R., J.-Y.D., J.-C.A., J.H.) and Service de Neurologie D (V.D., M.F.), Hôpital Neurologique, Hospices Civils de Lyon; Institut NeuroMyoGene INSERM U1217/CNRS UMR 5310 (L.-D.D., E.C., V.D., B.J., F.D., V.R., J.-Y.D., J.-C.A., J.H.), Université de Lyon-Université Claude Bernard Lyon 1; Université Grenoble Alpes (S.B., Y.C.), CEA, iRTSV-BGE, Inserm 1038, Grenoble; EA 3082 (C.T.-A.), Université Lyon 2, France; Service of Neurology (L.B.), Hospital Universitario Fundación Alcorcón, Madrid, Spain; Service de Neurologie (B.L., F.T.), CHU Bordeaux and UMR CNRS 5293 Université de Bordeaux; Unité de Neurologie Cognitive, Epilepsie et Pathologie du Mouvement (J.C.), Explorations Fonctionnelles Neurologiques, Hôpital Pierre Paul Riquet, Toulouse; Service de Neurologie (T.D.B.), Hopital Delafontaine, Saint-Denis; Neurology (C.L.-F.), University Hospital Pasteur 2, Nice; Département de Neurologie (J.-Y.D.), Groupe Hospitalier Pitié-Salpêtrière, Paris; and Neurology Department (J.-C.A.), CHU Saint-Etienne, France.
Objective: To report 10 patients with limbic encephalitis (LE) and adenylate kinase 5 autoantibodies (AK5-Abs).
Methods: We conducted a retrospective study in a cohort of 50 patients with LE with uncharacterized autoantibodies and identified a specific target using immunohistochemistry, Western blotting, immunoprecipitation, mass spectrometry, and cell-based assay.
Results: AK5 (a known autoantigen of LE) was identified as the target of antibodies in the CSFs and sera of 10 patients with LE (median age 64 years; range 57-80), which was characterized by subacute anterograde amnesia without seizure and sometimes preceded by a prodromal phase of asthenia or mood disturbances.
Neurol Neuroimmunol Neuroinflamm
October 2016
Université Paris-Est (F.L., M.L.), INSERM U955, Laboratoire Psychiatrie Translationnelle, et AP-HP, DHU Pe-PSY, Pole de Psychiatrie et d'Addictologie des Hôpitaux Universitaires Henri Mondor, et Fondation FondaMental, Créteil; French Reference Center on Paraneoplastic Neurological Syndrome (L.T., G.P., V.D., F.D., V.R., D.P., J.-C.A., J.-Y.D., J.H.), Hospices Civils de Lyon, Hôpital Neurologique, Bron; Institut NeuroMyoGene (INMG) INSERM U1217/CNRS UMR 5310 (L.T., V.D., F.D., V.R., J.-C.A., J.H.), Lyon; Université de Lyon-Université Claude Bernard Lyon 1 (L.T., V.D., F.D., J.H.); AP-HP (D.P., J.-Y.D.), Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, Paris; Service de Neurologie (J.-C.A.), CHU de Saint-Etienne et Université de Lyon, Saint-Etienne; Inserm (J.-Y.D.), U 1127, CNRS, UMR 7225, ICM, Sorbonne Universités, UPMC Univ Paris 06, UM 75 Paris; and Université de Bordeaux (L.G.), Interdisciplinary Institute for Neuroscience, UMR 5297, France.
Objective: To precisely describe the initial psychiatric presentation of patients with anti-NMDA receptor (NMDAR) antibodies encephalitis (anti-NMDAR encephalitis) to identify potential clues enhancing its early diagnosis.
Methods: We retrospectively studied the French Reference Centre medical records of every adult patient with anti-NMDAR encephalitis to specify the patients' initial psychiatric symptoms leading to hospitalization in a psychiatric department and the reasons underlying the diagnosis of anti-NMDAR encephalitis.
Results: The medical records of 111 adult patients were reviewed.
J Neurol
May 2016
Department of Neurology, Haukeland University Hospital, Bergen, Norway.
Prostate cancer is the most common cancer among American and European men. Nervous system affection caused by local tumor growth or osseous metastases are the main causes of neurological symptoms in prostate cancer patients. Prostate cancer is rarely reported in association with paraneoplastic neurological syndromes (PNS).
View Article and Find Full Text PDFEur J Neurosci
June 2016
Institut NeuroMyoGène, INSERM U1217/UMR CNRS 5310, Lyon, France.
In the last few years, a rapidly growing number of autoantibodies targeting neuronal cell-surface antigens have been identified in patients presenting with neurological symptoms. Targeted antigens include ionotropic receptors such as N-methyl-d-aspartate receptor or the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, metabotropic receptors such as mGluR1 and mGluR5, and other synaptic proteins, some of them belonging to the voltage-gated potassium channel complex. Importantly, the cell-surface location of these antigens makes them vulnerable to direct antibody-mediated modulation.
View Article and Find Full Text PDFLancet Neurol
April 2016
Neuroimmunology Program, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. Electronic address:
Encephalitis is a severe inflammatory disorder of the brain with many possible causes and a complex differential diagnosis. Advances in autoimmune encephalitis research in the past 10 years have led to the identification of new syndromes and biomarkers that have transformed the diagnostic approach to these disorders. However, existing criteria for autoimmune encephalitis are too reliant on antibody testing and response to immunotherapy, which might delay the diagnosis.
View Article and Find Full Text PDFJAMA Neurol
April 2016
French Reference Center on Paraneoplastic Neurological Syndrome, Hospices Civils de Lyon, Lyon, France2Institut Neuro-MyoGene, INSERM U1217/CNRS UMR 5310, Université Claude Bernard Lyon 1, Lyon, France.
Neurol Neuroimmunol Neuroinflamm
December 2015
Neurology Department and Stroke Center (C.L., A.-C.Z., I.T., F.P.), Versailles Mignot Hospital, Versailles; Versailles Saint Quentin en Yvelines University (C.L., A.-C.Z., I.T., F.P.); Nuclear Medicine Department (E.L.S.), Foch Hospital, Suresnes; French Reference Center on Paraneoplastic Neurological Syndrome (J.H.), Department of Neuro-oncology, Hospices Civils de Lyon, Hôpital Neurologique, Bron; Lyon Neuroscience Research Center INSERM U1028/CNRS UMR 5292 (J.H.), Lyon; and Université de Lyon-Université Claude Bernard Lyon 1 (J.H.), France.
Neurol Neuroimmunol Neuroinflamm
December 2015
Lyon Neuroscience Research Center (V.D., A.C., C. Bost, F.D., V.R., C. Blanc, O.P., J.-C.A., J.H.), INSERM U1028/CNRS UMR 5292; Université de Lyon-Université Claude Bernard Lyon 1 (V.D., A.C., C. Bost, F.D., V.R., C. Bardel, O.P., J.H.); the Department of Neurology D (V.D.) and French Reference Center on Paraneoplastic Neurological Syndrome (A.V., C. Bost, F.D., G.P., V.R., M.-O.C., C. Blanc, J.-C.A., J.-Y.D., J.H.), Hospices Civils de Lyon, Hôpital Neurologique, Bron; Service de Biostatistique (C. Bardel), Hospices Civils de Lyon, CNRS UMR 5558; Laboratoire de Biométrie et Biologie Evolutive (C. Bardel), Equipe Biostatistique-Santé, Villeurbanne; the Department of Biopathology (I.T.), Centre de Recherche en Cancérologie de Lyon; Service de Neurologie (J.-C.A.), CHU de Saint-Etienne et Université de Lyon, Saint-Etienne; and Service de Neurologie Mazarin (J.-Y.D.), Groupe Hospitalier Pitié-Salpêtrière, APHP, Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière, UMR S975, CNRS, UMR 7225, Paris, France.
Objective: To evaluate the presence of immunoglobulin A (IgA) subtype of anti-NMDA receptor (NMDAR) antibodies (IgA-NMDAR-Abs) in the CSF of patients with immunoglobulin G (IgG)-NMDAR-Ab encephalitis and to describe the potential association with a specific clinical pattern.
Methods: The retrospective analysis for the presence of IgA-NMDAR-Abs in 94 CSF samples from patients with anti-NMDAR encephalitis diagnosed between October 2007 and February 2014 was conducted at the French Reference Centre on Paraneoplastic Neurological Syndrome. This observational study compared 39 patients with both IgA- and IgG-NMDAR-Abs to 55 patients with only IgG-NMDAR-Abs.
J Neurol Sci
November 2015
Reference Center for Neuromuscular Diseases and ALS, Hôpital de la Timone, Marseille, France.
We retrospectively analyzed three patients with pure motor neuronopathy followed for more than four years in our center. The patients presented a rapidly progressive lower motor neuron syndrome (LMNS) over the course of a few weeks leading to a severe functional impairment. The neurological symptoms preceded the diagnosis of a breast adenocarcinoma and a thymoma in the first two patients, one of them with anti-CV2/CRMP5 antibodies.
View Article and Find Full Text PDFMol Psychiatry
September 2015
Department of Psychiatry, College of Medicine, The Ohio State University, Columbus, OH, USA.
Front Cell Neurosci
July 2015
Aix Marseille Université, CNRS, Centre de Recherche en Neurobiologie et Neurophysiologie de Marseille, CRN2M-UMR7286, Faculté de Médecine Nord Marseille, France.
Contactin-associated protein-like 2 (Caspr2), also known as CNTNAP2, is a cell adhesion molecule that clusters voltage-gated potassium channels (Kv1.1/1.2) at the juxtaparanodes of myelinated axons and may regulate axonal excitability.
View Article and Find Full Text PDFMol Psychiatry
September 2015
Department of Psychiatry, College of Medicine, The Ohio State University, Columbus, OH, USA.
Neuronal polarity and spatial rearrangement of neuronal processes are central to the development of all mature nervous systems. Recent studies have highlighted the dynamic expression of Collapsin-Response-Mediator Proteins (CRMPs) in neuronal dendritic/axonal compartments, described their interaction with cytoskeleton proteins, identified their ability to activate L- and N-type voltage-gated calcium channels (VGCCs) and delineated their crucial role as signaling molecules essential for neuron differentiation and neural network development and maintenance. In addition, evidence obtained from genome-wide/genetic linkage/proteomic/translational approaches revealed that CRMP expression is altered in human pathologies including mental (schizophrenia and mood disorders) and neurological (Alzheimer's, prion encephalopathy, epilepsy and others) disorders.
View Article and Find Full Text PDFRev Neurol (Paris)
October 2014
Neuro-oncologie, French Reference Center on Paraneoplastic Neurological Syndrome, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, 59, boulevard Pinel, 69677 Bron cedex, France; Lyon Neuroscience Research Center, Inserm U1028/CNRS UMR 5292, faculté Laennec, 9, rue Guillaume-Paradin, 69003 Lyon, France; Université de Lyon, université Claude-Bernard Lyon 1, 43, boulevard du 11 novembre 1918, 69100 Villeurbanne, France. Electronic address:
Initially, antibodies targeting intracellular compounds were described in patients with paraneoplastic neurological syndromes (PNS) such as anti-Hu, anti-Yo, anti-Ri or anti-CV2/CRMP5 antibodies. As more than 90% of patients with these antibodies suffer from an associated cancer, these antibodies were used as biomarkers of an underlying tumour. Recently, autoantibodies targeting cell-surface synaptic antigens have been described in patients with neurological symptoms suggesting PNS.
View Article and Find Full Text PDFEur J Neurol
May 2014
French Reference Center on Paraneoplastic Neurological Syndrome, Department of Neuro-oncology, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France; Lyon Neuroscience Research Center INSERM U1028/CNRS UMR 5292, Lyon, France; Université de Lyon - Université Claude Bernard Lyon 1, Lyon, France.
Background And Purpose: To describe the characteristics of patients presenting a paraneoplastic cerebellar degeneration without classical onconeural antibodies (seronegative PCD).
Methods: Thirty-nine seronegative PCD patients from the Paraneoplastic Neurological Syndrome Euronetwork were retrospectively analyzed and compared with 180 patients with PCD associated with classical onconeural antibodies (seropositive PCD).
Results: No patient had anti-CASPR2 or anti-mGluR1 antibodies.
Neurology
February 2014
From the French Reference Center on Paraneoplastic Neurological Syndrome (A.V, V.D., F.D., G.P., G.C., V.R., J.-C.A., J.-Y.D., J.H.), Hospices Civils de Lyon, Hôpital Neurologique, Neuro-Oncology, Bron; Lyon Neuroscience Research Center (A.V., V.D., F.D., J.-C.A., J.H.), INSERM U1028/CNRS UMR 5292, Lyon; Université de Lyon-Université Claude Bernard Lyon 1 (A.V., V.D., F.D., J.H.), Lyon; Service de Neurologie (J.-C.A.), CHU de Saint-Etienne, Saint-Etienne; and Service de Neurologie Mazarin (J.-Y.D.), Groupe Hospitalier Pitié-Salpêtrière, APHP, Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière, UMR S975, CNRS, UMR 7225, Paris, France.
Objective: The aim of this study was to describe the clinical features and specificities of adult male patients with NMDA receptor antibodies (NMDAr-Abs) encephalitis.
Methods: Observational study of 13 adult male patients who were diagnosed with NMDAr-Abs encephalitis at the French Paraneoplastic Neurological Syndrome Reference Center.
Results: Adult male patients frequently presented initially with a seizure (8/13, 61.
J Infect
May 2014
French Reference Center on Paraneoplastic Neurological Syndrome, Hospices Civils de Lyon, Hôpital Neurologique, Neuro-oncology, F-69677 Bron, France; Lyon Neuroscience Research Center, INSERM U1028/CNRS UMR 5292, F-69372 Lyon, France; Lyon University - Université Claude Bernard Lyon 1, F-69372 Lyon, France. Electronic address:
Background: For 60% of acute febrile encephalitis cases, the cause is unknown. Autoantibodies directed against different synaptic proteins or receptors in patients with autoimmune encephalitis have recently been described and could indicate a differential diagnosis of infectious encephalitis.
Objective: The aim of this study was to retrospectively investigate the presence of autoantibodies directed against synaptic proteins or receptors in patients with acute febrile encephalitis.
Neurology
October 2013
From the Department of Neurology (J.C.), Mayo Clinic Arizona, Scottsdale; and French Reference Center on Paraneoplastic Neurological Syndrome (J.H.), Hospices Civils de Lyon, Lyon Neuroscience Research Center, INSERM U1028/CNRS UMR 5292, Université Claude Bernard Lyon 1, France.
Neurology
June 2013
French Reference Center on Paraneoplastic Neurological Syndrome, Hospices Civils de Lyon, Hôpital Neurologique, Neurologie B, Bron, France.
Objective: The aim of this study was to describe the clinical presentation of children and adolescents with anti-Hu antibodies (Hu-Abs).
Methods: This was a retrospective study of children and adolescents with Hu-Abs collected by the French Paraneoplastic Neurological Syndrome (PNS) Reference Center between January 1, 2000 and December 31, 2011.
Results: The center identified 251 patients with Hu-Abs.